

Daniel J Sargent

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3680970/daniel-j-sargent-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

348 papers	39,733 citations	85 h-index	195 g-index
365 ext. papers	45,128 ext. citations	6.9 avg, IF	6.94 L-index

#	Paper	IF	Citations
348	A comparison of laparoscopically assisted and open colectomy for colon cancer. <i>New England Journal of Medicine</i> , 2004 , 350, 2050-9	59.2	2808
347	A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 23-30	2.2	1885
346	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013 , 381, 303-12	4 ⁰	1783
345	Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. <i>New England Journal of Medicine</i> , 2003 , 349, 247-57	59.2	1641
344	Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3219-26	2.2	1063
343	Guidelines 2000 for colon and rectal cancer surgery. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 583-96	9.7	1004
342	Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3677-83	2.2	955
341	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018 , 391, 2128-2139	4 ⁰	910
340	Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1209-14	2.2	888
339	Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. <i>Archives of Pathology and Laboratory Medicine</i> , 2000 , 124, 979-94	5	882
338	Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. <i>Annals of Surgery</i> , 2007 , 246, 655-62; discussion 662-4	7.8	796
337	A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. <i>New England Journal of Medicine</i> , 2001 , 345, 1091-7	59.2	784
336	Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1797-806	2.2	769
335	Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 1346-55	27.4	666
334	Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 303, 1729-37	27.4	586
333	Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). <i>Journal of Clinical Oncology</i> , 2008 , 26, 5326-34	2.2	561
332	Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 287, 321-8	27.4	557

331	Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8664-70	2.2	509
330	Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1043-8	2.2	442
329	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 1177-1188	59.2	429
328	Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9243-9	2.2	420
327	Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. <i>Archives of Surgery</i> , 2007 , 142, 298-303		406
326	Clinical trial designs for predictive marker validation in cancer treatment trials. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2020-7	2.2	406
325	Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. <i>Journal of Clinical Oncology</i> , 2009 , 27, 872-7	2.2	400
324	Revised TN categorization for colon cancer based on national survival outcomes data. <i>Journal of Clinical Oncology</i> , 2010 , 28, 264-71	2.2	397
323	A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. <i>Surgery</i> , 2005 , 138, 618-28; discussion 628-30	3.6	393
322	DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 863-75	9.7	390
321	Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4085-91	2.2	386
320	Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. <i>Journal of Clinical Oncology</i> , 2012 , 30, 263-7	2.2	380
319	Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1785-96	2.2	357
318	Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 1383-93	27.4	330
317	Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4027-34	2.2	302
316	Progression-free survival is a surrogate for survival in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5218-24	2.2	278
315	American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1277-80	2.2	273
314	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology</i> , 2016 , 17, 1709-1719	21.7	258

313	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology, The</i> , 2015 , 16, 937-48	21.7	240
312	Biomarkers and surrogate end points--the challenge of statistical validation. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 309-17	19.4	240
311	Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. <i>Gastroenterology</i> , 2009 , 137, 1270-9	13.3	229
310	Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5721-7	2.2	229
309	Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. <i>Gastroenterology</i> , 2015 , 148, 88-99	13.3	219
308	American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2016 , 66, 370-4	220.7	219
307	Comparison of artificial neural networks with other statistical approaches: results from medical data sets. <i>Cancer</i> , 2001 , 91, 1636-42	6.4	214
306	Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9441-2	2.2	209
305	Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 3408-15	12.9	193
304	Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3664-72	2.2	192
303	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1453-1486	2.2	191
302	End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4569-74	2.2	183
301	Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3227-33	2.2	182
300	Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3347-53	2.2	179
299	Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. <i>Journal of Clinical Oncology</i> , 2010 , 28, 256-63	2.2	177
298	Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. <i>Clinical Cancer Research</i> , 2012 , 18, 1506-12	12.9	176
297	Drug rechallenge and treatment beyond progression--implications for drug resistance. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 571-87	19.4	174
296	Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. <i>Biometrics</i> , 2011 , 67, 1047-56	1.8	173

295	Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2600-6	2.2	171
294	Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3895-902	2.2	168
293	Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial. <i>Annals of Surgery</i> , 2019 , 269, 589-595	7.8	168
292	Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. <i>Gastroenterology</i> , 2006 , 131, 729-37	13.3	166
291	Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1031-9	2.2	164
290	Obesity is an independent prognostic variable in colon cancer survivors. <i>Clinical Cancer Research</i> , 2010 , 16, 1884-93	12.9	160
289	Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1491-8	2.2	160
288	Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. <i>Journal of Clinical Oncology</i> , 2008 , 26, 183-9	2.2	153
287	Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2336-41	2.2	153
286	Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1735-43	2.2	148
285	Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 52, 469-75	4	141
284	Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	138
283	An adaptive dose-finding design incorporating both toxicity and efficacy. <i>Statistics in Medicine</i> , 2006 , 25, 2365-83	2.3	134
282	Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4620-6	2.2	131
281	Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1948-55	2.2	125
280	Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 54, 386-96	4	122
279	Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. <i>European Journal of Cancer</i> , 2013 , 49, 1565-77	7.5	119
278	The radial distance of extraprostatic extension of prostate carcinoma 1999 , 85, 2630-2637		118

277	The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. <i>Clinical Cancer Research</i> , 2010 , 16, 1764-9	12.9	117
276	Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected DukesB2 or C colon cancer: a North Central Cancer Treatment Group Study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1572-82	2.2	112
275	Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	109
274	KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). <i>Clinical Cancer Research</i> , 2014 , 20, 3033-43	12.9	105
273	Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. <i>Cancer</i> , 2013 , 119, 1528-36	6.4	104
272	Integrating biomarkers in clinical trials. <i>Expert Review of Molecular Diagnostics</i> , 2011 , 11, 171-82	3.8	104
271	Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1600-7	9.7	102
270	DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	101
269	Optimising the design of phase II oncology trials: the importance of randomisation. <i>European Journal of Cancer</i> , 2009 , 45, 275-80	7.5	98
268	Decrease in cranial nerve complications after radiosurgery for acoustic neuromas: a prospective study of dose and volume. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 43, 305-11	4	97
267	Counting degrees of freedom in hierarchical and other richly-parameterised models. <i>Biometrika</i> , 2001 , 88, 367-379	2	93
266	Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. <i>Bayesian Analysis</i> , 2012 , 7, 639-674	2.3	92
265	Clinical trial designs for predictive biomarker validation: one size does not fit all. <i>Journal of Biopharmaceutical Statistics</i> , 2009 , 19, 530-42	1.3	92
264	Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 843-53	2.2	90
263	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. <i>Current Colorectal Cancer Reports</i> , 2013 , 9, 261-269	1	82
262	Current issues in adjuvant treatment of stage II colon cancer. <i>Annals of Surgical Oncology</i> , 2006 , 13, 887-98	3.8	81
261	Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3671-6	2.2	79
260	Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2975-84	2.2	77

259	Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 211-27	9.7	77
258	Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3277-83	2.2	77
257	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. <i>Journal of Molecular Diagnostics</i> , 2017 , 19, 187-225	5.1	76
256	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 144-50	2.2	76
255	A General Framework for Random Effects Survival Analysis in the Cox Proportional Hazards Setting. <i>Biometrics</i> , 1998 , 54, 1486	1.8	76
254	Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. <i>Clinical Trials</i> , 2010 , 7, 312-21	2.2	74
253	Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. <i>PLoS ONE</i> , 2012 , 7, e42274	3.7	73
252	Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1936-41	2.2	72
251	Clinical implications of microsatellite instability in sporadic colon cancers. <i>Current Opinion in Oncology</i> , 2009 , 21, 369-73	4.2	72
250	Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1599-606	2.2	71
249	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 552-560	2.2	69
248	Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. <i>Journal of Clinical Oncology</i> , 2015 , 33, 22-8	2.2	69
247	Alternate endpoints for screening phase II studies. <i>Clinical Cancer Research</i> , 2009 , 15, 1873-82	12.9	68
246	Predictive biomarker validation in practice: lessons from real trials. <i>Clinical Trials</i> , 2010 , 7, 567-73	2.2	68
245	Adjuvant therapy in the elderly: making the right decision. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1870-5	2.2	68
244	Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	67
243	Method for evaluating prediction models that apply the results of randomized trials to individual patients. <i>Trials</i> , 2007 , 8, 14	2.8	67
242	Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4109-15	2.2	66

241	Assessing the measure of a new drug: is survival the only thing that matters?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1922-3	2.2	66
240	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. <i>JAMA Oncology</i> , 2018 , 4, 379-383	13.4	64
239	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 638-648	9.7	63
238	Adaptive adjustment of the randomization ratio using historical control data. <i>Clinical Trials</i> , 2013 , 10, 430-40	2.2	63
237	Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. <i>Clinical Cancer Research</i> , 2008 , 14, 5810-8	12.9	63
236	A three-outcome design for phase II clinical trials. <i>Contemporary Clinical Trials</i> , 2001 , 22, 117-25		63
235	Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. <i>Cancer</i> , 2004 , 101, 2170-6	6.4	62
234	Randomized phase II trials: inevitable or inadvisable?. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2641-7	2.2	61
233	End points in advanced colon cancer clinical trials: a review and proposal. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3572-5	2.2	61
232	A flexible design for multiple armed screening trials. <i>Statistics in Medicine</i> , 2001 , 20, 1051-60	2.3	61
231	Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. <i>American Journal of Gastroenterology</i> , 2006 , 101, 2818-25	0.7	60
230	Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. <i>JAMA Oncology</i> , 2017 , 3, 472-480	13.4	59
229	End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?. <i>Oncologist</i> , 2006 , 11, 624-9	5.7	59
228	Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1667-70	9.7	58
227	An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. <i>Statistics in Medicine</i> , 2007 , 26, 2317-30	2.3	58
226	Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3656-63	2.2	56
225	Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2848-54	2.2	56
224	Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998 , 41, 593-8	4	56

223	Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3469-74	2.2	56
222	Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. <i>International Journal of Clinical Oncology</i> , 2009 , 14, 102-11	4.2	55
221	Surgeon volume does not predict outcomes in the setting of technical credentialing: results from a randomized trial in colon cancer. <i>Annals of Surgery</i> , 2008 , 248, 746-50	7.8	55
220	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. <i>Archives of Pathology and Laboratory Medicine</i> , 2017 , 141, 625-657	5	54
219	Long-term follow-up and individual item analysis of quality of life assessments related to laparoscopic-assisted colectomy in the COST trial 93-46-53 (INT 0146). <i>Annals of Surgical Oncology</i> , 2011 , 18, 2422-31	3.1	54
218	Refining multimodal therapy for rectal cancer. <i>New England Journal of Medicine</i> , 2001 , 345, 690-2	59.2	54
217	Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). <i>Clinical Cancer Research</i> , 2015 , 21, 5294-304	12.9	53
216	Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. <i>Oncology</i> , 2009 , 77, 120-3	3.6	53
215	Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144. <i>Clinical Colorectal Cancer</i> , 2009 , 8, 88-93	3.8	52
214	Cost implications of new treatments for advanced colorectal cancer. <i>Cancer</i> , 2009 , 115, 2081-91	6.4	51
213	Issues in clinical trial design for tumor marker studies. <i>Seminars in Oncology</i> , 2002 , 29, 222-30	5.5	51
212	Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. <i>Clinical Cancer Research</i> , 2008 , 14, 8263-9	12.9	50
211	PHASE II STUDY OF PACLITAXEL AND CISPLATIN FOR ADVANCED UROTHELIAL CANCER. <i>Journal of Urology</i> , 2000 , 164, 1538-1542	2.5	50
210	Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. <i>Journal of Clinical Oncology</i> , 2010 , 28, 460-5	2.2	49
209	Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation. <i>Clinical Cancer Research</i> , 2005 , 11, 6466-71	12.9	49
208	ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	48
207	Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1498-506	9.7	47
206	Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges. <i>Statistics in Medicine</i> , 2010 , 29, 1077-83	2.3	47

205	Randomized phase II trials: time for a new era in clinical trial design. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 932-4	8.9	46
204	Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. <i>Lancet Oncology, The</i> , 2017 , 18, 143-154	21.7	45
203	Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4199-204	2.2	45
202	Clinical trial designs incorporating predictive biomarkers. <i>Cancer Treatment Reviews</i> , 2016 , 43, 74-82	14.4	44
201	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. <i>Lancet Oncology, The</i> , 2012 , 13, e196-204	21.7	43
200	General and statistical hierarchy of appropriate biologic endpoints. <i>Oncology</i> , 2006 , 20, 5-9	1.8	43
199	Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2016-23	2.2	42
198	Thymidylate synthase expression in colon carcinomas with microsatellite instability. <i>Clinical Cancer Research</i> , 2006 , 12, 2738-44	12.9	42
197	Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. <i>Clinical Cancer Research</i> , 2014 , 20, 4210-7	12.9	41
196	Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. <i>Clinical Cancer Research</i> , 2012 , 18, 256-62	12.9	41
195	Clinical trial designs for prospective validation of biomarkers. <i>Molecular Diagnosis and Therapy</i> , 2005 , 5, 317-25		39
194	Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3002-7	2.2	38
193	Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2781-6	2.2	38
192	Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. <i>Journal of Clinical Oncology</i> , 2012 , 30, 406-12	2.2	38
191	Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 100-9	3.8	36
190	Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). <i>Clinical Cancer Research</i> , 2014 , 20, 3319-27	12.9	36
189	Functional and clinical significance of variants localized to 8q24 in colon cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2492-500	4	36
188	Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse. <i>Journal of Clinical Oncology</i> , 2014 , 32, 841-50	2.2	35

187	Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. <i>Clinical Cancer Research</i> , 2008 , 14, 4128-33	12.9	35
186	Colon and Rectum 2017 , 251-274		35
185	Optimism bias leads to inconclusive results-an empirical study. <i>Journal of Clinical Epidemiology</i> , 2011 , 64, 583-93	5.7	34
184	5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. <i>Clinical Colorectal Cancer</i> , 2005 , 4, 325-31	3.8	34
183	Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9275-81	2.2	34
182	Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma. <i>Journal of Immunotherapy</i> , 2000 , 23, 430-7	5	34
181	Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5958-64	2.2	33
180	A flexible approach to time-varying coefficients in the Cox regression setting. <i>Lifetime Data Analysis</i> , 1997 , 3, 13-25	1.3	32
179	Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. <i>Cancer</i> , 2005 , 104, 1871-84	6.4	32
178	Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4574-80	2.2	32
177	Genotype-based clinical trials in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2015 , 12, 475-87	14.8	31
176	Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3205-10	2.2	31
175	Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. <i>International Journal of Oncology</i> , 2010 , 36, 601-6	4.4	31
174	Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4591-6	2.2	31
173	Systematic review of statistical methods used in molecular marker studies in cancer. <i>Cancer</i> , 2008 , 112, 1862-8	6.4	30
172	Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). <i>Cancer</i> , 2012 , 118, 1083-90	6.4	29
171	Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis. <i>Annals of Surgical Oncology</i> , 2011 , 18, 3261-70	3.1	29
170	Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?. <i>Lancet, The</i> , 2007 , 370, 105-107	40	29

169	. <i>Annals of Surgery</i> , 2003 , 237, 502-508	7.8	29
168	The radial distance of extraprostatic extension of prostate carcinoma 1999 , 85, 2630		29
167	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1929-1937	2.2	28
166	Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017 , 16, 124-128	3.8	28
165	Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes. <i>Journal of Clinical Pathology</i> , 2010 , 63, 530-7	3.9	28
164	Blinded independent central review of the progression-free survival endpoint. <i>Oncologist</i> , 2010 , 15, 492-57	5.7	28
163	Survival is not a good outcome for randomized trials with effective subsequent therapies. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4719-20; author reply 4720-1	2.2	28
162	A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive tract. <i>Cancer</i> , 2005 , 103, 559-68	6.4	28
161	What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?. <i>Oncologist</i> , 2010 , 15 Suppl 1, 19-23	5.7	27
160	Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials. <i>Biostatistics</i> , 2011 , 12, 478-97	9.7	27
159	Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. <i>International Journal of Cancer</i> , 2007 , 120, 1232-8	7.5	27
158	Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. <i>Cancer</i> , 2007 , 110, 670-7	6.4	27
157	A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 55, 1305-10	4	27
156	The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. <i>European Journal of Cancer</i> , 2014 , 50, 260-6	7.5	26
155	Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. <i>Clinical Colorectal Cancer</i> , 2006 , 6, 133-9	3.8	26
154	Statistical issues in tumor marker studies. <i>Archives of Pathology and Laboratory Medicine</i> , 2000 , 124, 1011-5	1.5	26
153	FDG-PET lymphoma demonstration project invitational workshop. <i>Academic Radiology</i> , 2007 , 14, 330-9	4.3	25
152	Robust Bayesian approaches for clinical trial monitoring. <i>Statistics in Medicine</i> , 1996 , 15, 1093-106	2.3	25

151	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). <i>Oncologist</i> , 2016 , 21, 1509-1521	5.7	24
150	Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2334-9	2.2	24
149	Surrogate endpoint validation: statistical elegance versus clinical relevance. <i>Statistical Methods in Medical Research</i> , 2008 , 17, 477-86	2.3	24
148	Raising the bar for antineoplastic agents: how to choose threshold values for superiority trials in advanced solid tumors. <i>Clinical Cancer Research</i> , 2015 , 21, 1036-43	12.9	23
147	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1182-9	2.2	22
146	Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials. <i>Statistics in Medicine</i> , 2012 , 31, 743-61	2.3	22
145	The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 179-87	3.8	22
144	Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. <i>Clinical Cancer Research</i> , 2011 , 17, 6592-9	12.9	22
143	Smoothing Balanced Single-Error-Term Analysis of Variance. <i>Technometrics</i> , 2007 , 49, 12-25	1.4	22
142	Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers. <i>Clinical Trials</i> , 2013 , 10, 647-52	2.2	21
141	Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. <i>Cancer</i> , 2011 , 117, 4155-65	6.4	21
140	Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. <i>Computational Statistics and Data Analysis</i> , 2011 , 55, 2748-2757	1.6	21
139	Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need?. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2978-81	2.2	21
138	Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 54, 409-13	4	21
137	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. <i>Journal of Oncology Practice</i> , 2017 , 13, 333-337	3.1	20
136	A review of phase II trial designs for initial marker validation. <i>Contemporary Clinical Trials</i> , 2013 , 36, 597-604	2.4	20
135	Surgical quality surrogates do not predict colon cancer survival in the setting of technical credentialing: a report from the prospective COST trial. <i>Annals of Surgery</i> , 2013 , 257, 102-7	7.8	20
134	FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3311-3	2.2	20

133	Intraoperative radiotherapy for head and neck and skull base cancer. <i>Head and Neck</i> , 2003 , 25, 217-25; discussion 225-6	4.2	20
132	Molecular Biomarkers for the Evaluation of Colorectal Cancer. <i>American Journal of Clinical Pathology</i> , 2017 , 147, 221-260	1.9	19
131	The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	19
130	Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). <i>Pharmacogenetics and Genomics</i> , 2016 , 26, 133-7	1.9	19
129	All-comers versus enrichment design strategy in phase II trials. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 658-60	8.9	19
128	Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. <i>Current Oncology Reports</i> , 2011 , 13, 42-9	6.3	19
127	Design of clinical trials for biomarker research in oncology. <i>Clinical Investigation</i> , 2011 , 1, 1629-1636		19
126	Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. <i>Cancer</i> , 2010 , 116, 1691-8	6.4	19
125	Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2313-21	2.2	19
124	Molecular testing for lymph node metastases as a determinant of colon cancer recurrence: results from a retrospective multicenter study. <i>Clinical Cancer Research</i> , 2014 , 20, 4361-9	12.9	18
123	Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. <i>Journal of Clinical Oncology</i> , 2010 , 28, 527-30	2.2	18
122	Adjuvant therapy for colon cancer--the pace quickens. <i>New England Journal of Medicine</i> , 2005 , 352, 2746-53	5.2	18
121	Current issues in oncology drug development, with a focus on Phase II trials. <i>Journal of Biopharmaceutical Statistics</i> , 2009 , 19, 556-62	1.3	17
120	Prediction of radial distance of extraprostatic extension from pretherapy factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 69, 411-8	4	17
119	Flexible Bayesian survival modeling with semiparametric time-dependent and shape-restricted covariate effects. <i>Bayesian Analysis</i> , 2016 , 11, 381-402	2.3	16
118	Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	16
117	Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit. <i>Clinical Trials</i> , 2012 , 9, 283-92	2.2	16
116	Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 1402-10	4	16

115	Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology. <i>JAMA Oncology</i> , 2017 , 3, e170123	13.4	14
114	Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	14
113	Is en-bloc resection of locally recurrent rectal carcinoma involving the urinary tract indicated?. <i>Annals of Surgical Oncology</i> , 2006 , 13, 740-4	3.1	14
112	Current use and surgical efficacy of laparoscopic colectomy in colon cancer. <i>Journal of the American College of Surgeons</i> , 2013 , 217, 56-62; discussion 62-3	4.4	13
111	Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling. <i>Biometrics</i> , 2012 , 68, 226-32	1.8	13
110	Bayesian variable selection with joint modeling of categorical and survival outcomes: an application to individualizing chemotherapy treatment in advanced colorectal cancer. <i>Biometrics</i> , 2009 , 65, 1030-40	1.8	13
109	Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. <i>Oncologist</i> , 2011 , 16, 859-67	5.7	13
108	A 2-stage phase II design with direct assignment option in stage II for initial marker validation. <i>Clinical Cancer Research</i> , 2012 , 18, 4225-33	12.9	13
107	A north central cancer treatment group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. <i>Cancer</i> , 2000 , 89, 1699-1705	6.4	13
106	Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 36-41	2.2	12
105	Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. <i>Scandinavian Journal of Gastroenterology</i> , 2012 , 47, 356-62	2.4	12
104	Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time. <i>Biometrics</i> , 2012 , 68, 248-57	1.8	12
103	Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1756-9	9.7	12
102	Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. <i>Clinical Trials</i> , 2011 , 8, 591-600	2.2	12
101	Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. <i>Cancer Investigation</i> , 2008 , 26, 439-44	2.1	12
100	Molecular diagnostics: assays, tissues, progress, and pitfalls. <i>Journal of Clinical Oncology</i> , 2003 , 21, 395-62.	2.2	11
99	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. <i>International Journal of Cancer</i> , 2016 , 139, 986-95	7.5	11
98	Center-Within-Trial Versus Trial-Level Evaluation of Surrogate Endpoints. <i>Computational Statistics and Data Analysis</i> , 2014 , 78, 1-20	1.6	10

97	On Bayesian methods of exploring qualitative interactions for targeted treatment. <i>Statistics in Medicine</i> , 2012 , 31, 3693-707	2.3	10
96	NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. <i>Oncologist</i> , 2009 , 14, 970-8	5.7	10
95	A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles. <i>Statistics in Medicine</i> , 2017 , 36, 67-80	2.3	9
94	Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 696-703	4	9
93	Disease-free survival in colon cancer: still relevant after all these years!. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1609-10	2.2	9
92	Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine. <i>Chinese Clinical Oncology</i> , 2014 , 3, 14	2.3	9
91	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. <i>European Journal of Cancer</i> , 2018 , 103, 205-213	7.5	9
90	Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). <i>Journal of Geriatric Oncology</i> , 2018 , 9, 24-31	3.6	8
89	Randomized phase II clinical trials. <i>Journal of Biopharmaceutical Statistics</i> , 2014 , 24, 802-16	1.3	8
88	Statistical considerations for the next generation of clinical trials. <i>Seminars in Oncology</i> , 2011 , 38, 598-604	4.5	8
87	Clinical trials data collection: when less is more. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5019-21	2.2	8
86	Causal Effects of Treatments for Informative Missing Data due to Progression/Death. <i>Journal of the American Statistical Association</i> , 2010 , 105, 912-929	2.8	8
85	Time to initiation of adjuvant chemotherapy and survival in colorectal cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 1199; author reply 1200	27.4	8
84	Sam Wieand, PhD. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4523-4525	2.2	8
83	A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot. <i>Quality of Life Research</i> , 2002 , 11, 37-45	3.7	8
82	Sample size and design considerations for phase II clinical trials with correlated observations. <i>Contemporary Clinical Trials</i> , 1999 , 20, 242-52		8
81	Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3579-3579	2.2	8
80	Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. <i>Oncologist</i> , 2017 , 22, 189-198	5.7	7

79	Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 1-11	2.8	7
78	Bayesian adaptive trial design for a newly validated surrogate endpoint. <i>Biometrics</i> , 2012 , 68, 258-67	1.8	7
77	Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival. <i>Clinical Trials</i> , 2011 , 8, 581-90	2.2	7
76	Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points. <i>Journal of Biopharmaceutical Statistics</i> , 2015 , 25, 857-77	1.3	6
75	Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4048-57	2.2	6
74	New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study. <i>Statistics in Medicine</i> , 2016 , 35, 3245-58	2.3	6
73	Calibration of quality-adjusted life years for oncology clinical trials. <i>Journal of Pain and Symptom Management</i> , 2014 , 47, 1091-1099.e3	4.8	6
72	CAUSAL EFFECTS OF TREATMENTS FOR INFORMATIVE MISSING DATA DUE TO PROGRESSION/DEATH. <i>Journal of the American Statistical Association</i> , 2010 , 105, 912-929	2.8	6
71	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. <i>Journal of Geriatric Oncology</i> , 2016 , 7, 422-429	3.6	6
70	Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. <i>Lung Cancer</i> , 2015 , 90, 281-7	5.9	5
69	The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. <i>Oncologist</i> , 2017 , 22, 1415-1418	5.7	5
68	Early stopping for benefit in National Cancer Institute-sponsored randomized Phase III trials: the system is working. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1543-4	2.2	5
67	Adjuvant therapy for colon cancer: learning from the past to inform the future. <i>Annals of Surgical Oncology</i> , 2010 , 17, 947-9	3.1	5
66	Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients 2015 , 2,		5
65	Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. <i>Chinese Clinical Oncology</i> , 2014 , 3,	2.3	5
64	Mining the ACCENT database: a review and update. <i>Chinese Clinical Oncology</i> , 2013 , 2, 18	2.3	5
63	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	4
62	Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. <i>Clinical Trials</i> , 2017 , 14, 611-620	2.2	4

61	The ARCAD clinical trials program: an update and invitation. <i>Oncologist</i> , 2012 , 17, 188-91	5.7	4
60	North Central Cancer Treatment Group--achievements and perspectives. <i>Seminars in Oncology</i> , 2008 , 35, 530-44	5.5	4
59	Pick the Winner Designs in Phase II Cancer Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 5-6	8.9	4
58	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. <i>Blood</i> , 2016 , 128, 3027-3027	2.2	4
57	Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3711-3712	2.2	3
56	Application of tumor measurement-based metrics in the real world. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4374	2.2	3
55	Reply to D.J. Stewart. <i>Journal of Clinical Oncology</i> , 2010 , 28, e652-e653	2.2	3
54	A false-discovery-rate-based loss framework for selection of interactions. <i>Statistics in Medicine</i> , 2008 , 27, 2004-21	2.3	3
53	Pick the Winner Designs in Phase II Cancer Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 5-6	8.9	3
52	Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer. <i>PLoS ONE</i> , 2014 , 9, e94727	3.7	3
51	Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2020 , 17, 100492	1.8	3
50	Surrogate End Points in Soft Tissue Sarcoma: Methodologic Challenges. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3949-3950	2.2	3
49	An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles. <i>Journal of Biopharmaceutical Statistics</i> , 2019 , 29, 271-286	1.3	3
48	Pick the winner designs in phase II cancer clinical trials. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 5-6	8.9	3
47	Improved Outcomes in Metastatic Colon Cancer: Giving Credit Where Credit Is Due. <i>JAMA Oncology</i> , 2015 , 1, 795-6	13.4	2
46	Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis. <i>Clinical Colorectal Cancer</i> , 2015 , 14, 99-105	3.8	2
45	New Adjuvant Trial Designs in Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2015 , 11, 326-334	1	2
44	The direct assignment option as a modular design component: an example for the setting of two predefined subgroups. <i>Computational and Mathematical Methods in Medicine</i> , 2015 , 2015, 210817	2.8	2

43	Rejoinder for "Meta-analysis for surrogacy: accelerated failure time models and semi-competing risks modelling". <i>Biometrics</i> , 2012 , 68, 245-247	1.8	2
42	Systemic therapy for elderly patients with gastrointestinal cancer. <i>Clinical Medicine Insights: Oncology</i> , 2011 , 5, 89-99	1.8	2
41	Adverse-event rates: journals versus databases. <i>Lancet, The</i> , 2007 , 369, 171-2	4.0	2
40	CAIRO and FOCUS [Authors'Reply. <i>Lancet, The</i> , 2007 , 370, 1905	4.0	2
39	Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study. <i>Blood</i> , 2016 , 128, 1102-1102	2.2	2
38	Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. <i>Transactions of the American Clinical and Climatological Association</i> , 2010 , 121, 21-32; discussion 32-3	0.9	2
37	Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials. <i>Chinese Clinical Oncology</i> , 2016 , 5, 80	2.3	2
36	Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. <i>European Journal of Cancer</i> , 2018 , 96, 115-124	7.5	1
35	A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups. <i>Journal of Biopharmaceutical Statistics</i> , 2018 , 28, 451-462	1.3	1
34	Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment. <i>Contemporary Clinical Trials</i> , 2014 , 38, 157-62	2.3	1
33	Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting analysis dates for the IDEA collaboration. <i>Forum of Clinical Oncology</i> , 2014 , 5, 1-7	0.3	1
32	A phase II flexible screening design allowing for interim analysis and comparison with historical control. <i>Contemporary Clinical Trials</i> , 2013 , 35, 128-37	2.3	1
31	Reply to M.A. Rosen et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e161-e161	2.2	1
30	Evolving end points for clinical trials in advanced colorectal cancer. <i>Current Colorectal Cancer Reports</i> , 2009 , 5, 135-139	1	1
29	Reply to S.A. Kesikli et al. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2288-2289	2.2	1
28	Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer: Review of the ACCENT collaborative group. <i>Current Colorectal Cancer Reports</i> , 2008 , 4, 155-159	1	1
27	Duffy-Santner confidence intervals for the two-stage three-outcome design. <i>Journal of Biopharmaceutical Statistics</i> , 2006 , 16, 875-80	1.3	1
26	Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. <i>Blood</i> , 2016 , 128, 1196-1196	2.2	1

- 25 A phase II trial design with direct assignment option for initial marker validation.. *Journal of Clinical Oncology*, **2012**, 30, 34-34 2.2 1
- 24 Genomic classifiers in colon cancer - clinical utility. *Gastrointestinal Cancer Research: GCR*, **2008**, 2, S35-7 1
- 23 Biomarkers-guided targeted drugs: new clinical trials design and practice necessity **2011**, 30-41 1
- 22 CRM Trials for Assessing Toxicity and Efficacy **2012**, 85-96 O
- 21 Reply to M. Chao et al. *Journal of Clinical Oncology*, **2009**, 27, e281-e281 2.2 O
- 20 Testing of evaluation bias for progression free survival endpoint in oncology clinical trials. *Statistics in Medicine*, **2016**, 35, 3923-32 2.3
- 19 Biomarker-driven Studies in Metastatic Colorectal Cancer (mCRC): Challenges and Opportunities. *The Journal of Oncopathology*, **2014**, 2, 37-45
- 18 Reply to C.D. Atkins. *Journal of Clinical Oncology*, **2010**, 28, e747-e747 2.2
- 17 Reply to P. Prassopoulos et al. *Journal of Clinical Oncology*, **2010**, 28, e82-e82 2.2
- 16 Reply to I.D. Nagtegaal et al. *Journal of Clinical Oncology*, **2010**, 28, e399-e400 2.2
- 15 Reply to F. Montagnani et al. *Journal of Clinical Oncology*, **2009**, 27, e134-e135 2.2
- 14 Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. *Clinical Colorectal Cancer*, **2009**, 8, 88-93 3.8
- 13 Clinical Trials of Novel and Targeted Therapies: Endpoints, Trial Design, and Analysis. *Translational Medicine Series*, **2007**, 1-10
- 12 Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). *International Journal of Statistics in Medical Research*, **2018**, 7, 137-146 3
- 11 Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance).. *Journal of Clinical Oncology*, **2017**, 35, 3516-3516 2.2
- 10 Clinical Validation of Biomarkers in Cancer **2010**, 227-250
- 9 Phase III Clinical Trials with Anticancer Agents **2011**, 163-188
- 8 Statistics and Clinical Trials **2012**, 223-237

7 Clinical Validation of Biomarkers **2013**, 353-367

6 Adjuvant treatment of stage II colon cancer: yes or no, what, when and why? **2013**, 6-19

5 Statistics and Clinical Trials **2016**, 239-252.e1

4 Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the Power of Pooled Individual Patient Data from Multiple Clinical Trials. *Current Colorectal Cancer Reports*, **2016**, 12, 251-259 1

3 Importance of randomization in early clinical trials. *Clinical Advances in Hematology and Oncology*, **2009**, 7, 249-51 0.6

2 Gastrointestinal Cancers81-104

1 Introduction to special issue on biomarker-based clinical trial designs in oncology. *Chinese Clinical Oncology*, **2015**, 4, 28 2.3